2025 AHA/ACC高血压指南与欧洲肾脏最佳实践评论
2025年AHA/ACC等多学会更新高血压指南,与2024 ESC和2023 ESH指南在药物治疗人群和多数患者目标血压(<130/80 mmHg)上基本一致,但在命名、低危人群用药及SBP<120 mmHg目标上存在差异。ERBP评论指出2025 AHA/ACC更早启动药物并追求更低目标,而2023 ESH避免主动追求SBP<120 mmHg,2024 KDIGO建议CKD患者SBP<120 mmHg。
要点
- 多数指南同意多数患者目标血压<130/80 mmHg,但SBP<120 mmHg的推荐不一致。
- 2025 AHA/ACC推荐高危或生活方式未控制者SBP≥130或DBP≥80即启动药物。
- 2023 ESH避免主动追求SBP<120 mmHg或DBP<70 mmHg,2024 KDIGO建议CKD SBP<120 mmHg。
核心结论
- 2025 AHA/ACC较其他近期指南更早启动药物治疗并追求更低血压目标。
- 指南间在命名、低危人群药物治疗及SBP<120 mmHg目标上存在分歧。
研究设计与样本
- 本文为欧洲肾脏最佳实践对2025 AHA/ACC高血压指南的评论。
主要发现
- 2025 AHA/ACC推荐高危或非高危但生活方式未纠正者SBP≥130 mmHg或DBP≥80 mmHg启动药物。
- 2025 AHA/ACC推荐目标SBP至少<130 mmHg,鼓励SBP<120 mmHg,DBP<80 mmHg。
- 2023 ESH建议避免主动追求SBP<120 mmHg或DBP<70 mmHg。
- 2024 KDIGO建议CKD患者目标SBP<120 mmHg。
关键数值与推荐
- 2025 AHA/ACC高血压定义为SBP≥130 mmHg或DBP≥80 mmHg。
- 2025 AHA/ACC目标SBP<130 mmHg(鼓励<120 mmHg),DBP<80 mmHg。
- 2024 ESC和2023 ESH对血压≥130-139或≥80-89 mmHg仅在高危组推荐药物。
- 2023 ESH建议避免主动追求SBP<120 mmHg或DBP<70 mmHg。
- 2024 KDIGO建议CKD患者SBP<120 mmHg。
临床怎么用
- 肾内科医生应了解2025 AHA/ACC更早启动药物和更低目标的推荐。
- 对CKD患者需注意2024 KDIGO建议SBP<120 mmHg与2023 ESH避免SBP<120 mmHg的差异。
- 临床决策应结合患者心血管风险个体化血压目标。
局限性
- 本文为评论,未提供原始研究数据或系统评价。
- 指南间差异可能影响临床实践的统一性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
American Scientific Societies (AHA/ACC and others) updated in 2025 the guideline on High Blood Pressure following 2024 ESC and 2023 ESH updates from Europe. Guidelines mostly agree on who should receive pharmacotherapy and on a common target of systolic blood pressure (SBP; <130 mmHg) and diastolic blood pressure (DBP) <80 mmHg for most, as well as on individualizing BP targets according to patient characteristics. However, they differ in nomenclature, pharmacotherapy for people at lower cardiovascular risk and aiming at SBP <120 mmHg. Overall, 2025 AHA/ACC supports pharmacotherapy earlier and achieving lower BP targets than other recent guidelines: it recommends [high cardiovascular disease (CVD) risk] or finds reasonable (not high CVD risk, if not corrected by lifestyle) initiating pharmacotherapy for hypertension, defined as SBP ≥130 mmHg or DBP ≥80 mmHg. The recommended (high CVD risk) or reasonable (not high CVD risk) target is SBP at least <130 mmHg, with encouragement to achieve SBP <120 mmHg, and DBP <80 mmHg. However, 2024 ESC and 2023 ESH use alternative terms (high normal or elevated blood pressure) for blood pressure values (i.e. ≥130-139 or ≥80-89 mmHg) that require pharmacotherapy only in high-risk groups. Additionally, 2023 ESH recommends avoiding actively aiming for SBP <120 mmHg or DBP <70 mmHg. 2024 KDIGO avoids the term hypertension and suggests a target SBP <120 mmHg for people with chronic kidney disease. It would be desirable that guidelines converge on such key issues as nomenclature and therapeutic targets.
引用
- Kanbay M, Copur S, Sarafidis P, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a commentary from the European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2026. PMID: 41805831. doi:10.1093/ndt/gfag055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。